IECA Functional Genomics Mini-symposium

Neil Armstrong Hall of Engineering, Room 3109
Purdue University, West Lafayette, IN, USASaturday,

April 17, 2010

9:00  Welcome Barry L. Wanner
9:10   Session 1 Introduction Daisuke Kihara (Convener)
9:15   Bernhard O. Palsson (San Diego, USA)
The Operational Annotation of the E. coli Genome Obtained Through Integration of Multiple Genome-Scale Data Types
9:50  John F. Hunt (New York City, USA)
From genomics to protein structure and function
10:25   Break
10:55   Session 2 - Introduction Daoguo “Joe” Zhou (Convener)
11:00   Hirotada Mori (Ikoma, Japan)
New era for network analyses of Escherichia coli
11:35   Enrique Morett (Cuernavaca, Mexico)
Massive 5′end mRNA, TSSs, and TUs mapping with Illumina GAIIx technology
Noon Lunch
1:30   Session 3 - Introduction Walid Aref (Convener)
1:35   Tyrrell Conway (Norman, USA)
E. coli Gene Expression Database
2:10   Julio Collado-Vides (Cuernavaca, Mexico)
The transcriptional regulatory network of E. coli: integration and phenotypic landscape
2:45   Jay C. D. Hinton (Dublin, Ireland)
Title TBA
3:20   Break
3:50   Session 4 - Introduction Michael R. Gribskov (Convener)
3:55   David W. Ussery (Lyngby, Denmark)
The minimal set of conserved proteins across a thousand bacterial genomes
4:30   Speaker TBA
Title TBA
5:05   Joerg Vogel (Berlin/Wuerzburg)
Differential RNA-seq discovers the primary transcriptome of Helicobacter pylori
5:40   Wrap-up Barry L. Wanner
7:00   Dinner

March 2nd, 2010

3RD ANNUAL BIOMARKERS CONFERENCE

An essential addition from discovery to approval in clinical development

23rd - 24th March 2010, BSG Conference Centre, London, UK

Pharmaceutical and biotech companies are looking for new ways to increase the efficiency of drug discovery process while minimising costs and time for approvals. Biomarkers are fast becoming an essential part of clinical development from discovery to approval. According to industry research, the global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 %.

Additionally, the use of proteomics in biomarker testing and identification has boosted the services for biomarkers. A large number of companies now have commercialised biomarker tests employing a variety of technologies. However, there are several barriers and challenges that must be overcome behind these technologies.

Visiongain is proud to present its 3rd Annual Biomarker Conference, which will be held in London UK on 23-24 March 2010.This conference will enable you to identify and overcome challenges on how to incorporate biomarkers into your discovery programs as well as highlighting new technologies and strategies to improved prevention and care approaches.

more details…

March 1st, 2010

Next Posts Previous Posts


Pages

Categories

Links

Feeds